Management of patientswith follicular lymphoma treated first linewith obinutuzumab (vol 15, pg 3, 2019)

被引：0
|
作者：
Opat, S.
Dickinson, M.
Cheah, C. Y.
机构：
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷 / 05期
关键词：
D O I：
10.1111/ajco.13245
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E204 / E204
页数：1
相关论文
共 50 条
  • [1] Management of patients with follicular lymphoma treated first line with obinutuzumab
    Opat, Stephen
    Dickinson, Michael
    Cheah, Chan Yoon
    Tam, Constantine
    Boulos, Joy
    Thorburn, Alison Nicole
    Trotman, Judith
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2019, 15 : 3 - 11
  • [2] Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy
    Jamois, Candice
    Gibiansky, Ekaterina
    Gibiansky, Leonid
    Buchheit, Vincent
    Sahin, Denis
    Cartron, Guillaume
    Marcus, Robert
    Hiddemann, Wolfgang
    Seymour, John F.
    Strefford, Jonathan C.
    Hargreaves, Chantal E.
    Meneses-Lorente, Georgina
    Frey, Nicolas
    Fingerle-Rowson, Guenter
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1495 - 1506
  • [3] Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study
    Pott, Christiane
    Hoster, Eva
    Kehden, Britta
    Unterhalt, Michael
    Herold, Michael
    van der Jagt, Richard H.
    Janssens, Ann
    Kneba, Michael
    Mayer, Jiri
    Pocock, Chris
    Danesi, Nathalie
    Fingerle-Rowson, Gunter
    Harbron, Chris
    Mundt, Kirsten
    Marcus, Robert E.
    Hiddemann, Wolfgang
    BLOOD, 2016, 128 (22)
  • [4] Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression (vol 104, pg 1202, 2019)
    Seymour, John F.
    Marcus, Robert
    Davies, Andrew
    Gallop-Evans, Eve
    Grigg, Andrew
    Haynes, Andrew
    Herold, Michael
    Illmer, Thomas
    Nilsson-Ehle, Herman
    Soekler, Martin
    Duenzinger, Ulrich
    Nielsen, Tina
    Launonen, Aino
    Hiddemann, Wolfgang
    HAEMATOLOGICA, 2020, 105 (05) : 1465 - 1465
  • [5] A Favorable Outcome of Grade 3 Follicular Lymphoma Treated With Surgery and Obinutuzumab Combined With Chemotherapy: A Case Report and Literature Review
    Mekheal, Erinie
    Kania, Brooke E.
    Roman, Sherif
    Mekheal, Nader
    Kumar, Vinod
    Bondili, Leena
    Maroules, Michael
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (03)
  • [6] Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety (vol 36, pg 2395, 2018)
    Hiddemann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (27) : 2815 - 2815
  • [7] Seronegative West Nile Virus in a Patient With Stage 4 Follicular Cell Lymphoma (vol 27, pg 290, 2019)
    Sterrett, Yamini
    Katikineni, Veena
    Nayak, Rahul
    Piechowiak, Mary
    Delman, Mark
    INFECTIOUS DISEASES IN CLINICAL PRACTICE, 2020, 28 (01) : 33 - 33
  • [8] AMYPAD Diagnostic and Patient Management Study: Rationale and design (vol 15, pg 388, 2019)
    Frisoni, G. B.
    ALZHEIMERS & DEMENTIA, 2019, 15 (11) : 1505 - 1505
  • [9] Aneurysmal Subarachnoid Hemorrhage: Management by the Advanced Practice Provider (vol 15, pg 553, 2019)
    Troiani, Luigi
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2019, 15 (09): : A8 - A9
  • [10] Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial (vol 20, pg 43, 2019)
    Moreno, C.
    Greil, R.
    Demirkan, F.
    LANCET ONCOLOGY, 2019, 20 (01): : E10 - E10
12345